CX3CL1 and melanoma: Interestingly, preinfusion levels of IL15, Flt3-L, and FKN in clinical products of transgenic T cell receptor (TCR) T cells targeting MART-1 and NYESO-1 in clinical trials for melanoma correlated with response to treatment [83].